Downregulation and growth inhibitory role of FHL1 in lung cancer

International Journal of Cancer

Volumn 130, Issue 11, 2012, Pages 2549-2556

  Niu, Chang ^a,b   Liang, Chaoyang ^c   Guo, Juntang ^c   Cheng, Long ^a   Zhang, Hao ^a   Qin, Xi ^a   Zhang, Qunwei ^d   Ding, Lihua ^a   Yuan, Bin ^a   Xu, Xiaojie ^a   Li, Jiezhi ^a   Lin, Jing ^c   Ye, Qinong ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

cell cycle; cell growth; FHL1; lung cancer

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FOUR AND A HALF LIN 11 ISL 1 MAC 3 PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION;

ADULT; AGED; ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIM DOMAIN PROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; MIDDLE AGED; MUSCLE PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 83455161078     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26259     Document Type: Article

References (35)

1. Herbst RS, Heymach JV, Lippman SM,. Molecular origins of cancer: lung cancer. N Engl J Med 2008; 359: 1367-80.
2. Mulshine JL,. Clinical issues in the management of early lung cancer. Clin Cancer Res 2005; 11: 4993s-8s.
3. Webb JD, Simon MC,. Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle 2010; 9: 4098-105.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
6. Hammerman PS, Jänne PA, Johnson BE,. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15: 7502-9.
7. Toyooka S, Tsuda T, Gazdar AF,. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003; 21: 229-39.
8. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT,. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005; 26: 1770-3.
9. Johannessen M, Møller S, Hansen T, Moens U, Van Ghelue M,. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 2006; 63: 268-84.
10. Cowling BS, McGrath MJ, Nguyen MA, Cottle DL, Kee AJ, Brown S, Schessl J, Zou Y, Joya J, Bönnemann CG, Hardeman EC, Mitchell CA,. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol 2008; 183: 1033-48.
11. Gaussin V, Tomlinson JE, Depre C, Engelhardt S, Antos CL, Takagi G, Hein L, Topper JN, Liggett SB, Olson EN, Lohse MJ, Vatner SF, et al. Common genomic response in different mouse models of beta-adrenergic-induced cardiomyopathy. Circulation 2003; 108: 2926-33.
12. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG, Goldberg GS,. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 2008; 99: 1326-33.
13. Ding L, Niu C, Zheng Y, Xiong Z, Liu Y, Lin J, Sun H, Huang K, Yang W, Li X, Ye Q,. FHL1 interacts with estrogen receptors and regulates breast cancer cell growth. J Cell Mol Med 2011; 15: 72-85.
14. Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, Zhang H, Lin J, Cheng L, Qin X, et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest 2009; 119: 349-61.
15. Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, Hirakawa K, Mori M,. Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol 2008; 15: 2293-300.
16. Shen Y, Jia Z, Nagele RG, Ichikawa H, Goldberg GS,. SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res 2006; 66: 1543-52.
17. Zhang H, Xie X, Zhu X, Zhu J, Hao C, Lu Q, Ding L, Liu Y, Zhou L, Liu Y, Huang C, Wen C, et al. Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem 2005; 280: 43188-97.
18. Fang JL, McGarrity LJ, Beland FA,. Interference of cell cycle progression by zidovudine and lamivudine in NIH3T3 cells. Mutagenesis 2009; 24: 133-41.
19. Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E,. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res 2010; 704: 12-20.
20. Park KH, Seol JY, Yoo CG, Kim YW, Han SK, Lee EH, Kim CM, Shim YS, Lee CT,. Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer 2001; 31: 149-55.
21. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM,. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-86.
22. Volm M, Koomägi R, Mattern J, Stammler G,. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 1997; 75: 1774-8.
23. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
24. Lew DJ, Dulic V, Reed SI,. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991; 66: 1197-206.
25. Galaktionov K, Beach D,. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1992; 67: 1181-94.
26. Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, Borner MM, Betticher DC,. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003; 21: 2085-93.
27. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J,. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007; 55: 1-14.
28. Cooper WA, Kohonen-Corish MR, McCaughan B, Kennedy C, Sutherland RL, Lee CS,. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009; 55: 28-36.
29. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L,. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60: 4000-4.
30. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH,. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
31. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H,. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002; 20: 3865-71.
32. Lin J, Ding L, Jin R, Zhang H, Cheng L, Qin X, Chai J, Ye Q,. Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140 kDa (RIP140) interact and cooperate in estrogen signaling. Int J Biochem Cell Biol 2009; 41: 1613-8.
33. Jiang F, Yin Z, Caraway NP, Li R, Katz RL,. Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia 2004; 6: 623-35.
34. Ushijima T,. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223-31.
35. Matsumoto M, Kawakami K, Enokida H, Toki K, Matsuda R, Chiyomaru T, Nishiyama K, Kawahara K, Seki N, Nakagawa M,. CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. Int J Mol Med 2010; 26: 241-7.